During the bid defense we felt that you worked well as team and are very dynamic. Preparation of such a complex dossier really needs to be done in such a way.
VP Regulatory Affairs
In order to gain market access in pharma and remain competitive, pharmaceutical and medical technology manufacturers must be able to demonstrate clinical and economic evidence to providers, healthcare decision-makers and payers.
In the past, market access for a drug depended almost exclusively on efficacy and safety. These factors are still critical, but today, clinical differentiation and its effects on cost effectiveness is gaining importance. Today, more than ever, pharmaceutical companies must demonstrate how a new drug improves patient outcomes, reduces the burden of the healthcare system as a whole and is worth its price. To satisfy these criteria, pharmaceutical manufacturers have gradually expanded their business “beyond the pill” to build an evidence based strategy and therefore a stronger value story for payers.
For payers and market access stakeholders, the drug value proposition encompasses the optimal combination of disease need, clinical efficacy and economic impact that achieves market access at an optimal price, by validating and communicating the need for treatment and the value of utilizing the drug in question. To do so, market access activities have expanded beyond pricing and reimbursement, and include other elements in the drug development continuum such as:
We can help you navigate the increasingly complicated legislative environment. Each stakeholder has their own particular interest in a product, and we can help you communicate the value of your product to stakeholders.
During the bid defense we felt that you worked well as team and are very dynamic. Preparation of such a complex dossier really needs to be done in such a way.
PharmaLex is dedicated to delivering a comprehensive portfolio while their modular approach allows tailor-made solutions. They acknowledge our feedback, modify their approach and adapt accordingly.
We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for
This can be specific information about signing up to the newsletter.
Pellentesque lobortis, tellus at ultrices ullamcorper, lectus tellus consectetur lectus, id consequat leo quam quis eros. Mauris pellentesque tortor a augue pellentesque ultricies. Phasellus sit amet suscipit orci, vel dapibus ligula. Maecenas at pellentesque lectus, sit amet tristique felis. Integer fringilla risus ac neque mollis, at imperdiet lacus sodales. In vehicula orci sed vulputate interdum. Nunc sagittis non nunc eget sollicitudin.
Maecenas a mattis erat. Phasellus cursus erat non nisl pulvinar ultricies. Aenean id fringilla libero. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Morbi in ultrices elit. Suspendisse egestas hendrerit est. Integer pellentesque nisl ut justo tempus, nec suscipit dolor luctus. Cras vestibulum elementum tincidunt.
In compliance with the Spanish Law 15/1999, of Protection of Personal Data and in accordance with regulations approved by the Spanish RD 994/1999 inform you that your data will be part of a file located in Friedrichsdorf (Germany), whose ownership belongs to Pharmalex Spain S.L.U. The purpose of these data is the insertion in a potential job selection process. Inform the user that at any time may exercise their right of access, rectification, and deletion of data through email curriculum@pharmalex.com or to this postal address Pharmalex Spain. Coso 103, 50001 Zaragoza, Spain.